Friday, August 19, 2016 3:28:03 PM
It's ridiculous to say that the "MS thing is a joke". They received Orphan Designation from the FDA for the treatment of pediatric MS. That's not easy to get. They have to have a clear proof of the drug working to be able to get that designation. Now with Vanderputten in the company - I think that they'll finally move on that.
Also - what huge interest? Rik gets 4% on the money he put in - which was about $3M dollars in total. AND - he doesn't take a salary and has never sold any shares.
Lastly - they're not $50M in debt. They have a TOTAL LOSS SINCE INCEPTION of about $50M. That includes all of the stock paid out in the last 16 years. There are Biotech companies that have nothing and are already $100 - $150M in losses. I really think that Nutra Pharma has done more on less than any other biotech in history.
JMHO - we'll see what happens in the next few months - GLTYA
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM